{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:54:12Z","timestamp":1794020052866,"version":"4.8.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jaip.2025.10.046","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T07:43:21Z","timestamp":1763797401000},"page":"19-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Diagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6301-4520","authenticated-orcid":false,"given":"Cem","family":"Akin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"G\u00fclen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana C.","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke Oude","family":"Elberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.10.046_bib1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40413-018-0187-2","article-title":"The importance of allergic disease in public health: an iCAALL statement","volume":"11","author":"Sanchez-Borges","year":"2018","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2025.10.046_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.10.046_bib4","doi-asserted-by":"crossref","first-page":"e70024","DOI":"10.1111\/imr.70024","article-title":"IgE-mediated activation of mast cells and basophils in health and disease","volume":"331","author":"Charles","year":"2025","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaip.2025.10.046_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1067\/mai.2002.120524","article-title":"Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase","volume":"109","author":"Brockow","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jdermsci.2025.05.006","article-title":"Mast cells express IL17A, IL17F and RORC in lesional psoriatic skin, are activated before therapy and persist in high numbers in a resting state with IL-17A positivity after treatment","volume":"119","author":"Benezeder","year":"2025","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaip.2025.10.046_bib7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1365-4632.2012.05745.x","article-title":"Mast cells in cutaneous tumors: innocent bystander or maestro conductor?","volume":"53","author":"Biswas","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaip.2025.10.046_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00281-016-0565-1","article-title":"IgE and mast cells in host defense against parasites and venoms","volume":"38","author":"Mukai","year":"2016","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaip.2025.10.046_bib9","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.jaip.2022.05.007","article-title":"Global Classification of Mast Cell Activation Disorders: an ICD-10-CM-adjusted proposal of the ECNM-AIM Consortium","volume":"10","author":"Valent","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-025-00611-8","article-title":"Mastocytosis","volume":"11","author":"Akin","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaip.2025.10.046_bib12","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1016\/j.jaip.2024.08.044","article-title":"Harmonization of diagnostic criteria in mastocytosis for use in clinical practice: WHO vs ICC vs AIM\/ECNM","volume":"12","author":"Valent","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib13","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.jaip.2025.10.046_bib14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ajh.26966","article-title":"The international consensus classification of eosinophilic disorders and systemic mastocytosis","volume":"98","author":"Wang","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2025.10.046_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100397","article-title":"Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms","volume":"37","author":"Loghavi","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jaip.2025.10.046_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000329856","article-title":"Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms","volume":"157","author":"Alvarez-Twose","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cea.12369","article-title":"The presence of mast cell clonality in patients with unexplained anaphylaxis","volume":"44","author":"Gulen","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.10.046_bib18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaci.2017.05.036","article-title":"A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis","volume":"141","author":"Carter","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib19","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.jaip.2023.05.012","article-title":"Disease spectrum of anaphylaxis disorders","volume":"11","author":"Gonzalez de Olano","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib20","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/all.16109","article-title":"Mast cell activation identified through urine mediators","volume":"79","author":"Giannetti","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.10.046_bib21","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.jaip.2023.04.016","article-title":"Venom anaphylaxis: decision points for a more aggressive workup","volume":"11","author":"Bonadonna","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib22","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jaip.2015.03.015","article-title":"Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?","volume":"3","author":"Castells","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000501079","article-title":"Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome","volume":"180","author":"Valent","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib24","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jaci.2016.02.015","article-title":"Human IgE-independent systemic anaphylaxis","volume":"137","author":"Finkelman","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/all.15032","article-title":"European Academy of Allergy and Clinical Immunology, Food Allergy, Anaphylaxis Guidelines Group. EAACI guidelines: anaphylaxis (2021 update)","volume":"77","author":"Muraro","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.10.046_bib26","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jaip.2018.11.045","article-title":"Doctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib27","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaci.2018.06.004","article-title":"Mast cell activation syndrome: importance of consensus criteria and call for research","volume":"142","author":"Valent","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib28","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1016\/j.jaip.2021.06.011","article-title":"Selecting the right criteria and proper classification to diagnose mast cell activation syndromes: a critical review","volume":"9","author":"G\u00fclen","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/exd.13705","article-title":"Possible roles of basophils in chronic itch","volume":"28","author":"Hashimoto","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaip.2025.10.046_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2018.03.007","article-title":"Recent advancement in the mechanism of basophil activation","volume":"91","author":"Nakashima","year":"2018","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaip.2025.10.046_bib31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fmed.2017.00106","article-title":"Cysteinyl leukotrienes in eosinophil biology: functional roles and therapeutic perspectives in eosinophilic disorders","volume":"4","author":"Thompson-Souza","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2025.10.046_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/imr.70018","article-title":"Pathobiology and regulation of eosinophils, mast cells, and basophils in allergic asthma","volume":"331","author":"Whetstone","year":"2025","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaip.2025.10.046_bib33","first-page":"226","article-title":"Mediators of human mast cells and human mast cell subsets","volume":"58","author":"Schwartz","year":"1987","journal-title":"Ann Allergy"},{"key":"10.1016\/j.jaip.2025.10.046_bib34","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0889-8588(05)70300-2","article-title":"Serum tryptase and the laboratory diagnosis of systemic mastocytosis","volume":"14","author":"Schwartz","year":"2000","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaip.2025.10.046_bib35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2025.10.046_bib36","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaci.2021.08.007","article-title":"Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis","volume":"149","author":"Mateja","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib37","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2025.10.046_bib38","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.jaip.2022.05.003","article-title":"Incorporating tryptase genotyping into the workup and diagnosis of mast cell diseases and reactions","volume":"10","author":"Lyons","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaci.2021.06.017","article-title":"Hereditary alpha tryptasemia is not associated with specific clinical phenotypes","volume":"149","author":"Chollet","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib40","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jaci.2022.04.025","article-title":"Differential mast cell mediators in systemic mastocytosis and hereditary alpha-tryptasemia","volume":"150","author":"Giannetti","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11882-021-01010-1","article-title":"Hereditary alpha-tryptasemia: a commonly inherited modifier of anaphylaxis","volume":"21","author":"Wu","year":"2021","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2025.10.046_bib42","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.jaip.2022.03.008","article-title":"Nontryptase urinary and hematologic biomarkers of mast cell expansion and mast cell activation: status 2022","volume":"10","author":"Butterfield","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib43","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.jaip.2023.02.017","article-title":"Increased excretion of mast cell mediator metabolites during mast cell activation syndrome","volume":"11","author":"Butterfield","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11882-024-01128-y","article-title":"Urine mast cell mediators in the evaluation and diagnosis of mast cell activation syndrome","volume":"24","author":"Voelker","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2025.10.046_bib45","first-page":"27","article-title":"Biomarkers in the diagnosis of mast cell activation","volume":"25","author":"Voelker","year":"2025","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/cells11030329","article-title":"Mucosal mast cells as key effector cells in food allergies","volume":"11","author":"Nakano","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jaip.2025.10.046_bib47","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1503\/cmaj.060535","article-title":"Angioedema without urticaria: a large clinical survey","volume":"175","author":"Zingale","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.jaip.2025.10.046_bib48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1515\/dx-2020-0005","article-title":"Diagnosis of mast cell activation syndrome: a global \u201cconsensus-2\u201d","volume":"8","author":"Afrin","year":"2021","journal-title":"Diagnosis (Berl)"},{"key":"10.1016\/j.jaip.2025.10.046_bib49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jaci.2024.09.006","article-title":"Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria","volume":"155","author":"Solomon","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib50","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1016\/j.jaip.2025.06.009","article-title":"Rapid rise in unspecified mast cell activation diagnosis code usage in the United States","volume":"13","author":"Aleman","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib51","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jaip.2024.01.013","article-title":"Dilemma of mast cell activation syndrome: overdiagnosed or underdiagnosed?","volume":"12","author":"Akin","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib52","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1111\/all.15304","article-title":"Idiopathic mast cell activation syndrome is more often suspected than diagnosed\u2014a prospective real-life study","volume":"77","author":"Buttgereit","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.10.046_bib53","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaip.2023.11.041","article-title":"Low prevalence of idiopathic mast cell activation syndrome among 703 patients with suspected mast cell disorders","volume":"12","author":"Zaghmout","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib54","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.14309\/ajg.0000000000003201","article-title":"Mast cell activation syndrome and the triad of MCAS, POTS, and hypermobile EDS","volume":"120","author":"Weinstock","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaip.2025.10.046_bib55","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.cgh.2025.02.015","article-title":"AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review","volume":"23","author":"Aziz","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaip.2025.10.046_bib56","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.anai.2021.10.006","article-title":"Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy","volume":"128","author":"Novak","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib57","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12016-019-08755-8","article-title":"The relationship between hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS)","volume":"58","author":"Kucharik","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib58","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.5858\/arpa.2023-0070-OA","article-title":"Quantification of mucosal mast cells in the gastrointestinal tract: a primer for practicing pathologists","volume":"148","author":"Genta","year":"2024","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jaip.2025.10.046_bib59","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/PAS.0000000000000190","article-title":"A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients","volume":"38","author":"Doyle","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jaip.2025.10.046_bib60","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib61","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/ACI.0000000000000377","article-title":"Pharmacotherapy of mast cell disorders","volume":"17","author":"Gulen","year":"2017","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib62","first-page":"145","article-title":"Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks","volume":"8","author":"Roberts","year":"1982","journal-title":"Adv Shock Res"},{"key":"10.1016\/j.jaip.2025.10.046_bib63","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: a 2023 practice parameter update","volume":"132","author":"Golden","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.iac.2021.09.007","article-title":"Anaphylaxis and mast cell disorders","volume":"42","author":"G\u00fclen","year":"2022","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2025.10.046_bib65","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.amjmed.2013.09.008","article-title":"Recognition and first-line treatment of anaphylaxis","volume":"127","author":"Lieberman","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2025.10.046_bib66","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1398-9995.2010.02424.x","article-title":"Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review","volume":"65","author":"Choo","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.10.046_bib67","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1016\/j.jaip.2020.05.044","article-title":"Low frequency of IgE-mediated food hypersensitivity in mastocytosis","volume":"8","author":"Jarkvist","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib68","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/all.13980","article-title":"Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection","volume":"75","author":"Jarkvist","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.10.046_bib69","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jaip.2017.11.025","article-title":"Anaphylactic reactions after discontinuation of Hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected","volume":"6","author":"Bonadonna","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib70","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.iac.2014.02.004","article-title":"Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients","volume":"34","author":"Niedoszytko","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2025.10.046_bib71","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib72","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000249832","article-title":"A double-blind cross-over study of the effect of ketotifen in urticaria pigmentosa","volume":"166","author":"Czarnetzki","year":"1983","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaip.2025.10.046_bib73","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11154-016-9362-3","article-title":"Endocrine manifestations of systemic mastocytosis in bone","volume":"17","author":"Greene","year":"2016","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jaip.2025.10.046_bib74","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omalizumab in the treatment of adult patients with mastocytosis: a systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.10.046_bib75","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2024.11.004","article-title":"Omalizumab for mast cell disorders","volume":"155","author":"Akin","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib76","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1398-9995.2007.01604.x","article-title":"High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis","volume":"63","author":"Kontou-Fili","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.10.046_bib77","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jaci.2022.04.020","article-title":"Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet?","volume":"149","author":"Akin","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib78","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2025.10.046_bib79","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200339","article-title":"Avapritinib versus placebo in indolent systemic mastocytosis","volume":"2","author":"Gotlib","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jaip.2025.10.046_bib80","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaip.2025.10.046_bib81","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib82","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib83","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1365-2222.2009.03353.x","article-title":"Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells","volume":"39","author":"Krauth","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2025.10.046_bib84","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2015.242","article-title":"Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth","volume":"30","author":"Peter","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2025.10.046_bib85","first-page":"355","article-title":"Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V(+) systemic mastocytosis: a preclinical study","volume":"13","author":"Degenfeld-Schonburg","year":"2023","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jaip.2025.10.046_bib86","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.iac.2023.05.001","article-title":"Tyrosine kinase inhibitors in non-advanced systemic mastocytosis","volume":"43","author":"Akin","year":"2023","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2025.10.046_bib87","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.jaip.2021.02.040","article-title":"Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: prompt resolution of anaphylaxis with the addition of avapritinib","volume":"9","author":"Kudlaty","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib88","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jaci.2024.05.025","article-title":"Mast cell activation syndrome: current understanding and research needs","volume":"154","author":"Castells","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib89","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.jaip.2024.03.010","article-title":"Detecting changes in mast cell numbers versus activation in human disease: a roadblock for current biomarkers?","volume":"12","author":"Akin","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2025.10.046_bib90","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaci.2021.02.023","article-title":"Distinct plasma biomarkers confirm the diagnosis of mastocytosis and identify increased risk of anaphylaxis","volume":"148","author":"Gulen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2025.10.046_bib91","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejim.2023.07.026","article-title":"Thymic stromal lymphopoietin (TSLP) is a substrate for tryptase in patients with mastocytosis","volume":"117","author":"Marcella","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaip.2025.10.046_bib92","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jaci.2023.07.001","article-title":"Increased TIM-3 and galectin-9 serum levels in patients with advanced systemic mastocytosis","volume":"152","author":"Konantz","year":"2023","journal-title":"J Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825011146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825011146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:08:31Z","timestamp":1773907711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825011146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2213219825011146"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.10.046","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.10.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}